SV

Street Verdict

Analyst Scorecard

A record of what HSBC Analysis said publicly, with the source. Not advice.

Pending — not yet graded
“HSBC maintains a 'buy' rating on Biocon shares, following a significant boost from a ₹4,500 crore Qualified Institutional Placement (QIP). The QIP is expected to strengthen the company's financial position and support future growth initiatives, leading to a positive outlook for the stock.”

HSBC Analysis’s track record (trackable calls only): 34 graded calls · 95% CI 31–63%

BioconBullishCalled 19 Jun 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee HSBC Analysis’s full track record